Collaboration with the medical industry and KI innovations promotes translation of research findings into development of new drugs, biomarkers and treatments.
The StratCan research themes that have generated a high level of industry interest include studies of tumor microenvironment and its role in cancer development and treatment response, as well as efforts to identify and validate new drug targets and identify biomarkers or genetic markers predicting therapeutic response. The latter is especially important considering the strong industry interest to allocate patients to clinical studies where the chance of a beneficial response is best and where one can provide individualized and tailored cancer treatments.
To this end, technologies to count DNA and RNA molecules, as well as studies proving variable expression of established markers during tumor progression from local to metastatic disease, provide important contributions. The ongoing StratCan supported ClinSeq study paves the way for more effective drug development and future personalized care.
Commercialization of early discoveries
Karolinska Insitutet Innovations AB (KI Innovations) serves to support researchers at Karolinska Institutet in getting their research results developed to commercial products for the benefit of patients and society. StratCan works closely with KI Innovations and you are most welcome to turn to them with any questions you might have consering commercialization of your research ideas and results - no question is too small and it is never too early to approach them for a first discussion.